deferasirox has been researched along with Hematologic Malignancies in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hikota, R; Horiuchi, T; Kato, S; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Osawa, Y; Sato, K; Watanabe, J; Yamamura, T | 1 |
Maekawa, T; Yoshioka, S | 1 |
2 other study(ies) available for deferasirox and Hematologic Malignancies
Article | Year |
---|---|
Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Topics: Benzoates; Blood Proteins; Deferasirox; Drug Monitoring; Female; Ferritins; Hematologic Neoplasms; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multivariate Analysis; Prognosis; Protein Binding; Retrospective Studies; ROC Curve; Transfusion Reaction; Treatment Outcome; Triazoles | 2014 |
[Transfusion reaction and HLA antibodies].
Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |